NasdaqGS - Delayed Quote USD
Cabaletta Bio, Inc. (CABA)
At close: October 18 at 4:00 PM EDT
After hours: October 18 at 7:22 PM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Operating Expense
100,124.0000
74,660.0000
54,139.0000
46,313.0000
33,833.0000
--
Operating Income
-100,124.0000
-74,660.0000
-54,139.0000
-46,313.0000
-33,833.0000
--
Net Non Operating Interest Income Expense
10,141.0000
6,985.0000
1,164.0000
24.0000
494.0000
--
Pretax Income
-89,983.0000
-67,675.0000
-52,975.0000
-46,289.0000
-33,339.0000
--
Net Income Common Stockholders
-89,983.0000
-67,675.0000
-52,975.0000
-46,289.0000
-33,339.0000
--
Diluted NI Available to Com Stockholders
-90,456.0000
-67,675.0000
-52,975.0000
-46,289.0000
-33,339.0000
--
Basic EPS
-1.91
-1.65
-1.81
-1.80
-1.44
--
Diluted EPS
-1.91
-1.65
-1.81
-1.80
-1.44
--
Basic Average Shares
45,661.3140
39,192.4450
29,267.9560
25,716.1110
23,152.0830
--
Diluted Average Shares
46,972.4840
40,945.9500
29,267.9560
25,716.1110
23,152.0830
--
Total Operating Income as Reported
-100,124.0000
-74,660.0000
-54,139.0000
-46,313.0000
-33,833.0000
--
Total Expenses
100,124.0000
74,660.0000
54,139.0000
46,313.0000
33,833.0000
--
Net Income from Continuing & Discontinued Operation
-89,983.0000
-67,675.0000
-52,975.0000
-46,289.0000
-33,339.0000
--
Normalized Income
-89,983.0000
-67,675.0000
-52,975.0000
-46,289.0000
-33,339.0000
--
Interest Income
10,141.0000
6,985.0000
1,164.0000
24.0000
494.0000
--
Net Interest Income
10,141.0000
6,985.0000
1,164.0000
24.0000
494.0000
--
EBIT
-100,124.0000
-74,660.0000
-54,139.0000
-46,313.0000
-33,833.0000
--
EBITDA
-98,614.0000
-73,234.0000
-52,961.0000
-45,580.0000
-33,479.0000
--
Reconciled Depreciation
1,510.0000
1,426.0000
1,178.0000
733.0000
354.0000
--
Net Income from Continuing Operation Net Minority Interest
-89,983.0000
-67,675.0000
-52,975.0000
-46,289.0000
-33,339.0000
--
Normalized EBITDA
-98,614.0000
-73,234.0000
-52,961.0000
-45,580.0000
-33,479.0000
--
12/31/2019 - 10/25/2019
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
ALEC Alector, Inc.
4.9900
-3.11%
KYTX Kyverna Therapeutics, Inc.
5.64
-0.18%
AKRO Akero Therapeutics, Inc.
31.23
+1.33%
STOK Stoke Therapeutics, Inc.
13.00
-2.03%
LRMR Larimar Therapeutics, Inc.
7.76
-1.15%
PLRX Pliant Therapeutics, Inc.
15.20
+3.61%
NKTX Nkarta, Inc.
4.2600
+6.50%
RVMD Revolution Medicines, Inc.
50.43
+0.86%
TCRX TScan Therapeutics, Inc.
5.37
+2.09%
ETNB 89bio, Inc.
8.35
+1.71%